Performance evaluation comparison of 3 commercially available PCR-based KRAS mutation testing platforms

Julia A. Adams, Kristin M. Post, Sarah A. Bilbo, Xiaoyan Wang, Joyashree D. Sen, Anita J. Cornwell, Amanda J. Malek, Liang Cheng

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The identification of KRAS mutations in patients with certain types of cancer, including colonic adenocarcinoma and non-small cell lung carcinoma, has become increasingly important as these patients are contraindicated from receiving epidermal growth factor receptor-targeted therapies. Several polymerase chain reaction (PCR)-based tests are commercially available for KRAS mutation testing including Applied Biosystems KRAS Mutation Analysis on the ABI3130xl, Qiagen therascreen KRAS RGQ PCR on the Rotor-Gene Q MDx, and Qiagen KRAS Pyro on the PyroMark Q24; however, these tests have not been compared side by side. The purpose of this study was to evaluate the performance characteristics and workflow for 3 PCR-based methods of detecting KRAS mutation status. We evaluated the performance characteristics and workflow for 3 commercially available KRAS mutation detection platforms. All of the 188 samples run were successful, with 29% being positive for the KRAS mutation. Of the positive tests, Applied Biosystems detected 84% of the positive cases, whereas Qiagen therascreen RGQ and Qiagen KRAS Pyro detected 100% of the positive cases. In cases of discrepancy between Applied Biosystems and therascreen RGQ, Pyro agreed with therascreen RGQ 95% of the time. Qiagen therascreen RGQ and Pyro were comparable in terms of sensitivity, specificity, positive predictive value, negative predictive value, and accuracy, with all values being 100%. All 3 techniques accurately identified the appropriate mutation in the known control specimens. In summary, all 3 tests are relatively comparable for detecting the KRAS mutation, with Applied Biosystems having a slightly lower sensitivity, negative predictive value, and accuracy than therascreen RGQ and Pyro.

Original languageEnglish (US)
Pages (from-to)231-235
Number of pages5
JournalApplied Immunohistochemistry and Molecular Morphology
Volume22
Issue number3
StatePublished - 2014

Fingerprint

Polymerase Chain Reaction
Mutation
Workflow
vif Genes
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Colonic Neoplasms
Adenocarcinoma
Sensitivity and Specificity
Therapeutics

Keywords

  • Adenocarcinoma
  • Colorectal cancer
  • KRAS mutation
  • Lung cancer KRAS mutation
  • Molecular diagnostics
  • Personalized medicine
  • Targeted therapy
  • Test validation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology
  • Histology
  • Medicine(all)

Cite this

Performance evaluation comparison of 3 commercially available PCR-based KRAS mutation testing platforms. / Adams, Julia A.; Post, Kristin M.; Bilbo, Sarah A.; Wang, Xiaoyan; Sen, Joyashree D.; Cornwell, Anita J.; Malek, Amanda J.; Cheng, Liang.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 22, No. 3, 2014, p. 231-235.

Research output: Contribution to journalArticle

Adams, JA, Post, KM, Bilbo, SA, Wang, X, Sen, JD, Cornwell, AJ, Malek, AJ & Cheng, L 2014, 'Performance evaluation comparison of 3 commercially available PCR-based KRAS mutation testing platforms', Applied Immunohistochemistry and Molecular Morphology, vol. 22, no. 3, pp. 231-235.
Adams, Julia A. ; Post, Kristin M. ; Bilbo, Sarah A. ; Wang, Xiaoyan ; Sen, Joyashree D. ; Cornwell, Anita J. ; Malek, Amanda J. ; Cheng, Liang. / Performance evaluation comparison of 3 commercially available PCR-based KRAS mutation testing platforms. In: Applied Immunohistochemistry and Molecular Morphology. 2014 ; Vol. 22, No. 3. pp. 231-235.
@article{8ba5ad0a7bb24c0399e2aca2c474b53a,
title = "Performance evaluation comparison of 3 commercially available PCR-based KRAS mutation testing platforms",
abstract = "The identification of KRAS mutations in patients with certain types of cancer, including colonic adenocarcinoma and non-small cell lung carcinoma, has become increasingly important as these patients are contraindicated from receiving epidermal growth factor receptor-targeted therapies. Several polymerase chain reaction (PCR)-based tests are commercially available for KRAS mutation testing including Applied Biosystems KRAS Mutation Analysis on the ABI3130xl, Qiagen therascreen KRAS RGQ PCR on the Rotor-Gene Q MDx, and Qiagen KRAS Pyro on the PyroMark Q24; however, these tests have not been compared side by side. The purpose of this study was to evaluate the performance characteristics and workflow for 3 PCR-based methods of detecting KRAS mutation status. We evaluated the performance characteristics and workflow for 3 commercially available KRAS mutation detection platforms. All of the 188 samples run were successful, with 29{\%} being positive for the KRAS mutation. Of the positive tests, Applied Biosystems detected 84{\%} of the positive cases, whereas Qiagen therascreen RGQ and Qiagen KRAS Pyro detected 100{\%} of the positive cases. In cases of discrepancy between Applied Biosystems and therascreen RGQ, Pyro agreed with therascreen RGQ 95{\%} of the time. Qiagen therascreen RGQ and Pyro were comparable in terms of sensitivity, specificity, positive predictive value, negative predictive value, and accuracy, with all values being 100{\%}. All 3 techniques accurately identified the appropriate mutation in the known control specimens. In summary, all 3 tests are relatively comparable for detecting the KRAS mutation, with Applied Biosystems having a slightly lower sensitivity, negative predictive value, and accuracy than therascreen RGQ and Pyro.",
keywords = "Adenocarcinoma, Colorectal cancer, KRAS mutation, Lung cancer KRAS mutation, Molecular diagnostics, Personalized medicine, Targeted therapy, Test validation",
author = "Adams, {Julia A.} and Post, {Kristin M.} and Bilbo, {Sarah A.} and Xiaoyan Wang and Sen, {Joyashree D.} and Cornwell, {Anita J.} and Malek, {Amanda J.} and Liang Cheng",
year = "2014",
language = "English (US)",
volume = "22",
pages = "231--235",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Performance evaluation comparison of 3 commercially available PCR-based KRAS mutation testing platforms

AU - Adams, Julia A.

AU - Post, Kristin M.

AU - Bilbo, Sarah A.

AU - Wang, Xiaoyan

AU - Sen, Joyashree D.

AU - Cornwell, Anita J.

AU - Malek, Amanda J.

AU - Cheng, Liang

PY - 2014

Y1 - 2014

N2 - The identification of KRAS mutations in patients with certain types of cancer, including colonic adenocarcinoma and non-small cell lung carcinoma, has become increasingly important as these patients are contraindicated from receiving epidermal growth factor receptor-targeted therapies. Several polymerase chain reaction (PCR)-based tests are commercially available for KRAS mutation testing including Applied Biosystems KRAS Mutation Analysis on the ABI3130xl, Qiagen therascreen KRAS RGQ PCR on the Rotor-Gene Q MDx, and Qiagen KRAS Pyro on the PyroMark Q24; however, these tests have not been compared side by side. The purpose of this study was to evaluate the performance characteristics and workflow for 3 PCR-based methods of detecting KRAS mutation status. We evaluated the performance characteristics and workflow for 3 commercially available KRAS mutation detection platforms. All of the 188 samples run were successful, with 29% being positive for the KRAS mutation. Of the positive tests, Applied Biosystems detected 84% of the positive cases, whereas Qiagen therascreen RGQ and Qiagen KRAS Pyro detected 100% of the positive cases. In cases of discrepancy between Applied Biosystems and therascreen RGQ, Pyro agreed with therascreen RGQ 95% of the time. Qiagen therascreen RGQ and Pyro were comparable in terms of sensitivity, specificity, positive predictive value, negative predictive value, and accuracy, with all values being 100%. All 3 techniques accurately identified the appropriate mutation in the known control specimens. In summary, all 3 tests are relatively comparable for detecting the KRAS mutation, with Applied Biosystems having a slightly lower sensitivity, negative predictive value, and accuracy than therascreen RGQ and Pyro.

AB - The identification of KRAS mutations in patients with certain types of cancer, including colonic adenocarcinoma and non-small cell lung carcinoma, has become increasingly important as these patients are contraindicated from receiving epidermal growth factor receptor-targeted therapies. Several polymerase chain reaction (PCR)-based tests are commercially available for KRAS mutation testing including Applied Biosystems KRAS Mutation Analysis on the ABI3130xl, Qiagen therascreen KRAS RGQ PCR on the Rotor-Gene Q MDx, and Qiagen KRAS Pyro on the PyroMark Q24; however, these tests have not been compared side by side. The purpose of this study was to evaluate the performance characteristics and workflow for 3 PCR-based methods of detecting KRAS mutation status. We evaluated the performance characteristics and workflow for 3 commercially available KRAS mutation detection platforms. All of the 188 samples run were successful, with 29% being positive for the KRAS mutation. Of the positive tests, Applied Biosystems detected 84% of the positive cases, whereas Qiagen therascreen RGQ and Qiagen KRAS Pyro detected 100% of the positive cases. In cases of discrepancy between Applied Biosystems and therascreen RGQ, Pyro agreed with therascreen RGQ 95% of the time. Qiagen therascreen RGQ and Pyro were comparable in terms of sensitivity, specificity, positive predictive value, negative predictive value, and accuracy, with all values being 100%. All 3 techniques accurately identified the appropriate mutation in the known control specimens. In summary, all 3 tests are relatively comparable for detecting the KRAS mutation, with Applied Biosystems having a slightly lower sensitivity, negative predictive value, and accuracy than therascreen RGQ and Pyro.

KW - Adenocarcinoma

KW - Colorectal cancer

KW - KRAS mutation

KW - Lung cancer KRAS mutation

KW - Molecular diagnostics

KW - Personalized medicine

KW - Targeted therapy

KW - Test validation

UR - http://www.scopus.com/inward/record.url?scp=84909993215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909993215&partnerID=8YFLogxK

M3 - Article

C2 - 24614151

AN - SCOPUS:84909993215

VL - 22

SP - 231

EP - 235

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

IS - 3

ER -